Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U6 small nuclear 316, pseudogene (RNU6-316P)** is a *human pseudogene* corresponding to the U6 small nuclear RNA gene family[2]. U6 snRNAs are essential components of the spliceosome, the machinery responsible for removing introns from pre-mRNA during mRNA maturation[3][1]. However, **RNU6-316P** is a *processed pseudogene*: it does not encode a functional U6 snRNA but instead is an inactive genomic sequence derived from retrotransposition events involving U6 snRNA[5]. Such pseudogenes usually lack protein-coding ability and canonical biological or pharmacological function, but they can serve as genomic markers for studying retrotransposon activity and genome evolution[5]. There are many similar U6 snRNA pseudogenes in the human genome, reflecting the importance of the functional parent gene and the frequent occurrence of these events during evolution[5]. RNU6-316P is not a therapeutic target, is not involved in any known drug interactions, and has no documented physiological or pathological role.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 316, pseudogene (RNU6-316P).